Moderna and Merck mRNA cancer vaccine cuts death, recurrence risk by 42% in late-stage trial

Personalized treatment marks significant advance for melanoma, companies say

By LineZotpaper

Published23 October 2026

Read Time1 min

Pharmaceutical partners Merck and Moderna announced Thursday that their personalized mRNA vaccine for melanoma reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, a result the companies described as a milestone for the technology.

The vaccine, tailored to each patient’s tumor, targets the deadliest form of skin cancer. The companies said they are already engaging with regulatory authorities to seek approval, signaling a potential shift in cancer treatment.

“From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient’s tumor,” Moderna CEO Stéphane Bancel said in a statement. He called the trial results “a defining moment for that vision” and said they “reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer.”

The 42 percent reduction in death or recurrence over standard therapy alone bolsters broader hopes that mRNA vaccines and individualized cancer-targeting medicines offer a new paradigm for oncology. Merck and Moderna previously collaborated on an mRNA-based personalized cancer vaccine that showed promise in earlier trials.

Analysis

Why This Matters

If approved, this would be one of the first mRNA cancer vaccines, offering melanoma patients a significant survival benefit.
The success validates the approach of creating personalized vaccines tailored to each patient’s tumor mutations.
It strengthens the case for using mRNA technology against other cancers, potentially expanding treatment options.

Background

mRNA vaccines gained prominence during the COVID-19 pandemic for their rapid development and effectiveness. This trial applies the same platform to cancer, teaching the immune system to recognize and attack tumor-specific mutations. The late-stage results follow earlier Phase 2 data that had already shown promise.

Key Perspectives

Moderna and Merck: They view the results as a defining moment, proving that mRNA can be engineered to fight cancer as effectively as infectious diseases. Regulatory engagement is underway to bring the vaccine to patients. Patients: Those with melanoma could gain a new treatment that significantly reduces the risk of recurrence, potentially changing current standard of care.

What to Watch

Regulatory decisions in the US, Europe, and other markets over the coming months.
Expansion of trials to other cancers, such as lung or pancreatic, to see if the approach generalizes.
Competitive developments from other companies pursuing mRNA cancer vaccines.

Sources

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% · Ars Technica - All content

Checked

11 claims in this story checked against 1 source: 6 supported.

Show each claim

SupportedThe Moderna-Merck mRNA cancer vaccine reduced the risk of death or recurrence by 42% in a late-stage trial.Ars Technica - All content: “Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial”
Partly supportedThe companies described the result as a milestone for the technology.Ars Technica - All content: “The trial results “mark a defining moment for that vision and show what’s possible when we rethink how medicines are made.””
Partly supportedThe results are a significant advance for melanoma, as the companies say.Ars Technica - All content: “The results are a significant advance in melanoma treatment; Merck and Moderna are already engaging with regulatory authorities to get the vaccine approved.”
SupportedMerck and Moderna announced the trial result on Thursday.Ars Technica - All content: “pharmaceutical partners Merck and Moderna announced Thursday”
SupportedThe vaccine is personalized to each patient’s tumor and is for melanoma.Ars Technica - All content: “Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer”
SupportedThe companies are engaging with regulatory authorities to get the vaccine approved.Ars Technica - All content: “Merck and Moderna are already engaging with regulatory authorities to get the vaccine approved.”
SupportedModerna CEO Stéphane Bancel said the technology could enable cancer treatments matched to each patient’s tumor.Ars Technica - All content: ““From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient’s tumor,” Moderna CEO Stéphane Bancel said in a statement.”
Partly supportedBancel called the results “a defining moment for that vision.”Ars Technica - All content: “The trial results “mark a defining moment for that vision and show what’s possible when we rethink how medicines are made.””
SupportedBancel said the results “reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer.”Ars Technica - All content: “They also “reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer,” he said.”
Partly supportedThe 42% reduction was compared with standard therapy alone.Ars Technica - All content: “reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial”
Not in the sourcesMerck and Moderna had previously collaborated on a personalized mRNA cancer vaccine that showed promise in earlier trials.